Gallant Raises $18M Series B for Pet Stem Cell Therapies
- Editor
- Jun 30
- 2 min read
Whats Happening:
Gallant, an animal health biotechnology company, has secured $18 million in Series B financing to advance its off-the-shelf stem cell therapies for pets. The funding round was led by Digitalis Ventures, with participation from NovaQuest Capital Management and continued support from existing investors BOLD Capital and Hill Creek Partners. Gallant aims to create a new category in veterinary care with ready-to-use stem cell therapies targeting common and underserved diseases in dogs and cats.
Key Moves:
Gallant raises $18 million in Series B financing led by Digitalis Ventures
NovaQuest joins as a new investor, bringing experience from human FDA-approved stem cell therapy
Funding to accelerate FDA approval process and commercial rollout of lead product for feline chronic gingivostomatitis
By The Numbers:
$18 million raised in Series B financing
First product for FCGS on track for FDA conditional approval in early 2026
Only 56% of veterinarians satisfied with current canine OA treatments, 8% for FCGS
Key Quotes:
"We have been continually impressed by Gallant's team, clarity of vision, and ability to deliver," said Dr. Cindy Cole, Technical Partner at Digitalis Ventures.
"Regenerative medicine is entering its prime – we've seen it firsthand with the success of allogeneic stem cell therapies in human healthcare," said Brian Axe, Partner at NovaQuest.
"We're honored to have the backing of partners who share our vision in creating this new category of medicine that doesn't just help pets feel better, but helps pets get better," said Dr. Linda Black, CEO of Gallant.
Bottom Line:
Gallant's successful $18 million Series B funding round positions the company to potentially revolutionize veterinary care with off-the-shelf stem cell therapies. With its first product for feline chronic gingivostomatitis nearing FDA conditional approval, Gallant is poised to address significant unmet needs in pet health, potentially creating a new standard of care that targets the root causes of diseases rather than just managing symptoms.